Lipocine announces confirmation of dosing regimen for pivotal study of lpcn 1154

Positive clinical study results confirm 48-hour dosing regimen for the pivotal pk study on track for q2-24 pivotal study topline results and planned q4-24 nda filing  salt lake city , feb. 6, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system (cns) disorders by leveraging its proprietary platform, today announced that results from a multi-dose clinical study have confirmed the lpcn 1154 48-hour dosing regimen for the upcoming nda enabling pivotal pharmacokinetic (pk) study. lpcn 1154 is an oral neurosteroid being developed by lipocine for the treatment of postpartum depression (ppd).
LPCN Ratings Summary
LPCN Quant Ranking